VAPB Polyclonal Antibody, APC-Cy7 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-4227R-APC-Cy7-100uL |
| Product Name | VAPB Polyclonal Antibody, APC-Cy7 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Rat |
| Predicted Reactivity | Human, Mouse, Cow, Sheep, Pig, Horse, Chicken, Rabbit |
| Specifications | |
| Conjugation | APC-Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human VAPB |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 9217 |
| Subcellular location | Cytoplasm |
| Synonyms | ALS 8; ALS8; D2Abb2e; UNQ484/PRO983; Vamp 33b; VAMP associated 33 kDa protein; VAMP associated protein B and C; VAMP associated protein B; VAMP associated protein B/C; VAMP associated protein C; VAMP B; VAMP B VAMP C; VAMP B/VAMP C; VAMP C; VAMP vesicle associated membrane protein associated protein B and C; Vamp33b; VAMPB; VAMPB/VAMPC; VAMPC; VAP 33b; VAP B; VAP B/VAP C; VAP C; VAP33b; VAPB/VAPC; VAPC antibody Vesicle associated membrane protein associated protein B and C; Vesicle associated membrane protein associated protein B/C; VAPB_HUMAN. |
| Background | VAPB contains 1 MSP domain and it may play a role in vesicle trafficking. Defects in VAPB are a cause of proximal adult autosomal dominant spinal muscular atrophy [MIM:182980]; also called late onset spinal muscular atrophy Finkel type. Spinal muscular atrophies are neurodegenerative disorders characterized by degeneration of lower motor neurons, leading to progressive paralysis muscular atrophy. This form is a late adult onset form of the disease (after age 20 years). The patients show a benign course, most of them remaining ambulatory 10 to 40 years after clinical onset. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is VAPB Polyclonal Antibody, APC-Cy7 Conjugated (bs-4227R-APC-Cy7) validated for, and at what dilution?
bs-4227R-APC-Cy7 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does VAPB Polyclonal Antibody, APC-Cy7 Conjugated (bs-4227R-APC-Cy7) react with?
Tested reactivity: Rat. Predicted reactivity (expected from sequence homology but not yet tested): Human, Mouse, Cow, Sheep, Pig, Horse, Chicken, Rabbit.
How should bs-4227R-APC-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise VAPB Polyclonal Antibody, APC-Cy7 Conjugated (bs-4227R-APC-Cy7)?
KLH conjugated synthetic peptide derived from human VAPB
What are the excitation and emission wavelengths of the APC-Cy7 conjugate (bs-4227R-APC-Cy7)?
APC-Cy7 on bs-4227R-APC-Cy7: excitation / emission 650nm/780nm.